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women with PCOS compared with age-
matched controls.5
Women with PCOS have peripheral insu-
lin resistance independent of body mass
index (BMI), fat-free mass and fat distribu-
tion, with up to 60% of lean women with







Objectives: To determine the prevalence of glucose tolerance abnormalities and to 
identify associated risk factors in women with polycystic ovary syndrome (PCOS) 
attending a reproductive endocrinology clinic.
Design: Retrospective chart review.
Participants and setting: 372 women with confirmed PCOS attending a reproductive 
crinology clinic at Adelaide University’s Research Centre for Reproductive Health.
 outcome measures: Prevalence of glucose tolerance abnormalities and 
iation of such abnormalities with potential risk factors.
lts: 4.0% (15 women) had diabetes mellitus, 15.6% (58) had impaired glucose 
ance and 80.4% (299) had normal glucose tolerance. There was a significant trend 
rds increasing prevalence of diabetes with increasing age (odds ratio [OR], 0.60; 
P = 0.0085). The prevalence of abnormal glucose tolerance (diabetes and impaired 
glucose tolerance together) was significantly higher with higher waist circumference (OR, 
2.9; P = 0.05), higher body mass index (OR, 8.02; P = 0.0253), a family history of diabetes 
(OR, 1.56; P = 0.0192) and the presence of metabolic syndrome (OR, 5.62; P < 0.001).
Conclusion: The prevalence of diabetes and impaired glucose tolerance is high in 
women with PCOS, especially in older women and those with abdominal obesity and a 
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family history of diabetes.
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in P cystic ovary syndrome (PCOS) ise most frequent endocrine disorderwomen.1-4 Its clinical presentation
is heterogeneous, and commonly includes
menstrual irregularities, infertility, hir-
sutism, and acne. Metabolic syndrome and
its components are more common in
Most women with PCOS compensate fully
for their insulin resistance, but a substantial
proportion, especially those with first-
degree relatives with type 2 diabetes, have
decreased β-cell response to meals, or rising
glucose levels.10,11 Insulin resistance com-
bined with β-cell dysfunction results in an
increased prevalence of impaired glucose
tolerance (IGT) and type 2 diabetes mellitus
(DM) in these women.12,13
Previous studies in the United States have
shown that women with PCOS have a
higher prevalence of diabetes (8%–12%)
and impaired glucose tolerance (30%–35%)
than normal women of the same age.12,13 In
contrast, the prevalence of diabetes is lower
in Mediterranean regions, with an Italian
study reporting prevalences of 15.5% for
impaired glucose tolerance and 2.5% for
diabetes in women with PCOS.14 In a Dutch
follow-up study in a relatively lean popula-
tion of women with PCOS, the prevalence of
diabetes was increased compared with the
general female population, especially in
women aged 45–54 years.15
There is a paucity of published data on
the prevalence of glucose intolerance in
women with PCOS in Australia. Here, we
report a retrospective data analysis on a large
cohort of women with PCOS attending a
reproductive endocrinology clinic at our
centre. Our aims were to determine the
prevalence of glucose tolerance abnormali-
ties and to identify associated risk factors.
METHODS
Case records of 660 women presumed to
have PCOS because of a history of chronic
anovulation or infertility or oligomenorrhoea
or features of hyperandrogenism were
reviewed. These women were attending
reproductive endocrine clinics for treatment
of infertility or features of PCOS. PCOS was
confirmed in 372 women based on the pres-
ence of two of the following three features:
• chronic anovulation, oligomenorrhoea or
menstrual irregularities;
• clinical or biochemical evidence of
hyperandrogenism; and
• presence of polycystic ovaries on ultra-
sound in the absence of other disorders such
as hypothyroidism, Cushing’s syndrome,
hyperprolactinaemia or ovarian and adrenal
causes of hyperandrogenism.
These features are known as the Rotter-
dam 2003 criteria.16 Inclusion criteria were
a previously normal result on an oral glu-
cose tolerance test (OGTT), being contacta-
ble by phone and willingness to participate.
Exclusion criteria were no previous OGTT
and unwillingness to participate.
Information about: age; menarche; men-
strual cycles; presence or absence of hir-
sutism; acne; family history of diabetes and
PCOS; anthropometric measurements of
weight, height, waist circumference and
blood pressure; blood levels of various hor-
mones; and OGTT results with insulin and
lipid profile were collected from case notes.
Normal glucose tolerance (NGT), DM and
IGT were defined according to the criteria
proposed by the World Health Organiza-
tion.17 Impaired fasting glycaemia (IFG) was
defined by the recommendations of the
expert committee of the American Diabetes
Association.18 The presence of metabolic
syndrome was defined according to guide-
lines of the Third Report of the National
Cholesterol Education Program Expert
Panel.19 A family history of diabetes was
considered positive if any first-degree rela-
tive (parent or sibling) had a history of DM.
Body mass index (BMI) was calculated by
the formula: weight in kilograms/(height in
metres)2. A BMI of 18–25 was considered
normal, 25.01–30 overweight and > 30.01
obese. Measures of insulin resistance were
derived through homeostatic model assess-
ment for insulin resistance (HOMA-IR) and
the Quantitative Insulin Sensitivity Check
Index 1 (QUICKI1).20
Glucose was measured by the glucose
oxidase method, and other hormone levels
were measured by previously described
methods.21 Testosterone was measured by
radioimmunoassay (RIA) kits (Farmos Diag-
nostica, Turku, Finland). Insulin was meas-A • Volume 187 Number 6 • 17 September 2007
RESEARCHured by RIA kits from Pharmacia (Sydney,
NSW, Australia), and had a cross-reactivity
with proinsulin of about 20%. Intra-assay
and inter-assay coefficients of variation were
7% and 10%, respectively, for both testoster-
one and insulin.
Ethical approval was received from the
Human Research Ethics Committee of the
Women’s and Children’s Hospital, Adelaide.
Statistical analysis
All data are expressed as mean±SD and fre-
quencies (%). Categorical data were analysed
with the χ2 test, while analysis of variance or
Student’s t test were used to analyse the
difference between groups in continuous vari-
ables. A two-tailed P value of <0.05 was
considered statistically significant. SPSS soft-
ware, version 13 (SPSS Inc, Chicago, Ill, USA)
was used for statistical analysis.
RESULTS
The mean age of the 372 women with PCOS
was 30.3 ±5.6 years (median, 30.4 years;
range; 15–62 years), and their mean BMI
was 35.1 ±8.0 kg/m2. With the exception of
one woman, all of the 73 women with either
diabetes or IGT were overweight or obese
compared with 84% of the 299 women with
NGT. Forty-four per cent of all 372 women
had a family history of diabetes. The preva-
lences of oligomenorrhoea, hirsutism and
acne were 75%, 65% and 40%, respectively.
According to WHO criteria based on a 2-
hour postload glucose measurement during
an OGTT,17 of the 372 women with PCOS,
4.0% (15) had DM, 15.6% (58) had IGT,
and 80.4% (299) had NGT. When fasting
glucose levels were analysed according to
the recommendations of the American Dia-
betes Association,18 2.7% (10) had DM,
3.0% (11) had IFG and 94.6% (352) had
normal fasting glucose levels. The clinical
and biochemical features of the women
grouped according to their OGTT results are
summarised in Box 1.
Women who had diabetes were signifi-
cantly older (P = 0.003) than those who had
IGT or normal glucose tolerance (Box 1).
There was no difference between the three
groups in weight and BMI, but women with
diabetes or IGT had predominantly abdom-
inal obesity and a significantly higher waist
circumference (P = 0.001) than those in the
NGT group. There was no difference
between groups with respect to age of
menarche, frequency of menstrual irregular-
ities, acne and hirsutism.
As expected, the DM and IGT groups had
significantly higher fasting insulin levels
than the NGT group (P < 0.0001). Women
with diabetes and IGT had marked insulin
resistance as shown by the higher HOMA-IR
(P < 0 .0001)  a nd  l ow er  Q U ICKI1
(P < 0.0001) values compared with the NGT
group (Box 1). In the NGT group, obese
patients had significantly higher fasting and
2-hour glucose levels (P < 0.001), and they
were insulin resistant compared with nor-
mal-weight patients. Lipid profiles were
comparable in the three groups.
Box 2 shows the prevalence of glucose
tolerance abnormalities by age range for the
three groups. There was a significant trend
of an increasing prevalence of DM with
increasing age (P = 0.0085).
Box 3 examines the prevalence of abnor-
mal glucose tolerance in relation to age,
BMI, waist circumference, family history of
diabetes and metabolic syndrome. The prev-
alence of abnormal glucose tolerance (DM
and IGT together) was higher with higher
waist circumference (P = 0.05) and increased
BMI (P = 0.0253). A higher prevalence of
DM was seen in women with a family
history of diabetes (P = 0.0192) and in those
with metabolic syndrome (P < 0.001). When
multiple logistic regression was applied
using all these factors, only the presence of
metabolic syndrome was independently









No. of women 15 58 299
Age (years)† 35.7 ±6.5 30.7 ±4.8 29.9 ±5.5 0.003
Family history 
of diabetes
62% (8/13) 28% (16/47) 0.014
Weight (kg)† 103.1 ±23.7 101.8 ±21.6 92.0 ±20.6 0.051
BMI (kg/m2)† 38.3 ±8.2 37.9 ±7.5 35.14 ±7.60 0.047
Waist (cm)† 122.8 ±10.5 109.1 ±16.5 98.9 ±15.3 0.001
Testosterone (nmol/L)† 3.0 ±1.7 3.6 ±2.5 3.2 ±2.8 ns
Sex hormone binding 
globulin (nmol/L)†
16.1 ±15.2 19.7 ±18.7 27.6 ±28.9 ns
Fasting insulin (mIU/L)† 33.2 ±15.8 22.3 ±11.4 15.8 ±12.2 0.001
2-hour postload 
insulin (mIU/L)†
132.2 ±89.5 171.9 ±85.7 80.1 ±60.7 0.001
Fasting glucose to 
insulin ratio†
0.36 ±0.26 0.37 ±0.29 0.44 ±.26 0.001
HOMA-IR†‡ (ratio) 12.3 ±4.1 5.2 ±2.9 3.4 ±2.9 0.001
QUICKI1†‡ (ratio) 0.41 ±0.02 0.52 ±0.17 0.58 ±0.10 0.001
* One-way analysis of variance. † Values are mean ±SD. ‡ Measure of insulin resistance.
BMI = body mass index. ns = not significant. HOMA-IR = homeostatic model assessment for insulin resistance. 
QUICKI1 = Quantitative Insulin Sensitivity Check Index 1. ◆









14–20 16 0 6.3% (1) 93.8% (15)
> 20–25 45 2.2% (1) 11.1% (5) 86.7% (39)
> 25–30 118 1.7% (2) 15.3% (18) 83.1% (98)
> 30–35 127 3.9% (5) 19.7% (25) 76.4% (97)
> 35–40 48 4.2% (2) 16.7% (8) 79.2% (38)
> 40–45 12 25.0% (3) 8.3% (1) 66.7% (8)
> 45–50 2 50.0% (1) 0 50.0% (1)
> 50 1 0 0 100% (1)MJA • Volume 187 Number 6 • 17 September 2007 329
RESEARCHassociated with an increase in glucose toler-
ance abnormality (odds ratio, 2.213; 95%
CI, 1.061–4.617).
DISCUSSION
To our knowledge, this is the first study to
describe the range of glucose abnormalities
in an Australian population of women with
PCOS defined by the Rotterdam criteria. The
prevalence of DM in our study was 4.0%
and that of IGT was 15.6%, both of which
are higher than the prevalences of these
conditions in the general population of Aus-
tralian women of similar age.22 We have
previously reported a high rate of conver-
sion to glucose intolerance or DM in a
similar cohort.23 The high prevalences of
IGT and DM in this population are probably
the consequence of insulin resistance cou-
pled with obesity. These prevalences are
comparable to those reported in Italian
women with PCOS, but are lower than those
reported in women with PCOS in the US
and Asia.12-14,24 This discrepancy could be
the result of differences in the study popula-
tions or in the diagnostic criteria used to
define PCOS; another possible reason for
the discrepancy with the US study is the
prevalence of obesity, which is much higher
in the American population. It has been
shown that women with PCOS from South
Asia have higher fasting insulin concentra-
tions and lower insulin sensitivity than
white women.25 Much harder to define and
probably equally influential are the effects of
genetic, environmental and lifestyle factors
on the manifestation of the clinical features,
including insulin levels, in women with
PCOS.14
The above findings were based on 2-hour
postload OGTT results. If we base them on
fasting glucose levels, as recommended by
the American Diabetes Association, five
women diagnosed to have diabetes by
OGTT would have been missed. Similarly, in
an Australian study based on fasting glucose
levels, diabetes was diagnosed in 1.8% of
participants.26 This is substantially lower
than the rate of 2.9% based on 2-hour
postload glucose criteria alone, and than the
rate of 3.7% based on both the values, as
recommended by the WHO.26 Thus, 2-hour
postload OGTT may be required in popula-
tions at higher risk of diabetes, like women
with PCOS or certain ethnic groups.
Women with PCOS with obesity and glu-
cose intolerance are characteristically more
insulin resistant and have more hyperandro-
genism. It has been reported that there is a
higher frequency of oligomenorrhoea or hir-
sutism in women with IGT.14 However, we
found that frequencies of oligomenorrhoea,
hirsutism and acne and mean androgen
levels were comparable in all groups irre-
spective of OGTT results, and were higher
than those reported from Italy. This prob-
ably reflects a high proportion of infertile
patients in our study group.
We also identified demographic risk fac-
tors for developing DM or IGT in our
cohort. Women with DM were significantly
older than those with IGT and NGT, similar
to earlier reports.12,14 The significant trend
of increasing prevalence of DM with increas-
ing age concurs with the findings of previ-
ous studies.27  Obesity, particularly
abdominal obesity, increases the risk of DM.
Women with DM and IGT had a signifi-
cantly higher waist circumference than
women in the NGT group. The prevalence
of abnormal glucose tolerance (DM and IGT
together) was significantly higher among
women with a waist circumference over
88 cm. A family history of diabetes is an
important risk factor for glucose tolerance
abnormalities, and the prevalence of DM
was significantly higher in such women in
our cohort. It has previously been reported
that women with PCOS and DM had a 2.6-
fold higher prevalence of a family history of
DM.12 Insulin resistance and hyperinsuli-
naemia not only increase the risk of DM, but
are also correlated with an increased risk of
cardiovascular disease and are a main patho-
genic mechanism of metabolic syndrome.
The prevalence of DM was significantly
higher in women who had features of meta-
bolic syndrome.
The strengths of our study include its
having the largest cohort of women with
PCOS reported worldwide, that the diagno-
sis of PCOS was based on the newly estab-
lished Rotterdam 2003 criteria,16 and that
OGTT was prospectively carried out. Its
major limitations are its retrospective data
collection (resulting in some missing meas-
urements), and that patients were recruited
from an infertility clinic, so there could be a
selective bias to a particular type of PCOS.
To conclude, our study shows that the
prevalence of glucose intolerance abnormal-
ities is high in women with PCOS, especially
in older women and those with abdominal
obesity and a family history of diabetes. It is
recommended that all women with PCOS
have a 2-hour postload OGTT and lipid
profile testing at diagnosis. Regular follow-
up can be useful in both long-term clinical




3 Prevalence of abnormal oral glucose tolerance test outcome by potential 







glucose tolerance OR (95% CI)
Age (years) 
< 30 181 28 153 0.60 (0.35–1.03)
 30 188 44 144
Waist (cm)
> 88 195 40 155 2.90 (0.99–8.56)
 88 49 4 45
BMI (kg/m2) 
< 25 36 2 34 8.02 (1.87–34.38)
 25 219 67 142
Family history of diabetes 
Yes 91 24 67 1.56 (0.86–2.80)
No 192 36 156
Metabolic syndrome
Yes 100 36 64 5.62 (2.73–11.56)
No 132 12 120
*Diabetes mellitus and impaired glucose tolerance groups.
OR = odds ratio. BMI = body mass index. ◆330 MJA • Volume 187 Number 6 • 17 September 2007
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